Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNK-UT Cells for Steroid-Refractory/Resistant or Steroid-Dependent GVHD
NCT06568328Phase 1Recruiting
- Sponsor
- Fujian Medical University
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CNK-UT001 in graft-versus-host disease (GVHD), sponsored by Fujian Medical University. Primary endpoints: Incidence of Treatment Related adverse events at 1 year and Identification of Maximum Tolerated Dose & incidence of Dose-limiting Toxicities at 21 days. Started Sep 2024; status: recruiting.
02
Drugs
CNK-UT001
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06568328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568328.